What is in vivo CRISPR, and why does scaling matter?
In vivo CRISPR means editing genes directly inside the body, rather than removing cells, editing them in a lab, and putting them back (ex vivo). Scaling means moving from treating a handful of patients with ultra-rare mutations to treating common diseases like heart disease, diabetes, or cancer. If in vivo CRISPR can only fix one-in-a-million genetic typos, it's a scientific marvel but a public-health footnote. If it can lower cholesterol or rewire immune cells against solid tumors, it becomes a blockbuster tool. The evidence now shows both paths are opening.
The rare-disease proof of concept is strong—but that's not the ceiling
Two landmark clinical trials prove in vivo CRISPR works in humans for rare diseases. In the first, a single infusion of NTLA-2001 (a lipid nanoparticle carrying CRISPR machinery) reduced the disease-causing protein TTR by an average of 87% in patients with transthyretin amyloidosis, a fatal nerve and heart condition [8]. In the second, a similar therapy (NTLA-2002) for hereditary angioedema cut monthly swelling attacks by 95% across all dose groups, with the highest dose reducing the target protein by 95% [1]. Both trials reported only mild side effects. These are small studies (6 and 10 patients, respectively), but they prove the concept: a single shot can permanently edit a disease gene in the liver with dramatic clinical benefit. Critics might say these are still rare diseases, but the delivery platform—lipid nanoparticles targeting the liver—is the same one now being used for common conditions.
The big leap: common diseases like high cholesterol
The most direct evidence that in vivo CRISPR can scale to common diseases comes from a 2021 primate study targeting PCSK9, a gene that regulates LDL ('bad') cholesterol. A single infusion of lipid nanoparticles carrying a CRISPR base editor (a more precise version that changes a single DNA letter) knocked down PCSK9 protein by about 90% in the liver, leading to a roughly 60% drop in LDL cholesterol that remained stable for at least 8 months [3]. This is a 'once-and-done' approach to a condition that affects hundreds of millions of people worldwide. A 2025 review confirms that a CRISPR-based therapy targeting ANGPTL3 (CTX310) is now in development for high triglycerides, another common lipid disorder, and notes that 'in vivo CRISPR editing could enable a one-time, lifelong correction' [5]. The same lipid nanoparticle delivery system used in the rare-disease trials is being repurposed here, which dramatically lowers the regulatory and manufacturing hurdles.
Cancer and beyond: broader applications emerge
In vivo CRISPR is also moving into cancer, though mostly in preclinical models. One study used bacterial nanovesicles to deliver CRISPR directly to tumor-associated macrophages in mice, reprogramming them from a tumor-promoting to a tumor-killing state and inhibiting tumor growth [2]. Another engineered CAR-NK cells (a type of immune cell therapy) with a CRISPR-activated gene called OR7A10, achieving 100% complete responses in a mouse model of breast cancer [4]. While these are animal studies, they show the platform can be adapted for different cell types and delivery methods. A 2024 review sums up the field: 'despite the numerous ongoing clinical trials focusing on ex vivo genome editing, recent studies emphasize the therapeutic promise of in vivo gene editing' [7]. The key challenge for cancer is delivery—getting the CRISPR machinery into the right cells inside a solid tumor without harming healthy tissue—but the progress in delivery systems (lipid nanoparticles, AAV vectors, bacterial vesicles) is rapid [6].
About These Sources
This answer is built on 8 peer-reviewed studies — published from 2021 to 2026, 6 from 2024 or later, 5 in Q1 journals, collectively cited 2,337 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 82 papers retrieved from a database of over 500 million.
Sources used in this answer
CRISPR-Cas9 In Vivo Gene Editing of
Phase 1 trial of NTLA-2002 (in vivo CRISPR) for hereditary angioedema: single dose reduced target protein by up to 95% and monthly attack rate by 95% across 10 patients, with no serious adverse events.
Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy
Develops bacterial nanovesicles that deliver CRISPR-Cas9 to tumor-associated macrophages in mice, reprogramming them to an anti-tumor M1 phenotype and inhibiting tumor growth.
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
In nonhuman primates, a single infusion of lipid nanoparticles carrying a CRISPR base editor targeting PCSK9 achieved ~90% knockdown of the protein and ~60% reduction in LDL cholesterol that lasted at least 8 months.
OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours.
Identifies OR7A10 via in vivo CRISPR activation screen in CAR-NK cells; engineering this GPCR into CAR-NK cells achieved 100% complete response in an orthotopic breast cancer mouse model.
Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia.
Reviews ANGPTL3 inhibition strategies for hypertriglyceridemia, noting that CRISPR-based therapy (CTX310) could offer a one-time lifelong correction, pending phase 3 safety and efficacy data.
Advancements in CRISPR/Cas systems for disease treatment
Comprehensive review of CRISPR/Cas systems for disease treatment, highlighting delivery system performance and off-target effects as key hurdles for in vivo applications.
Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges
Review of in vivo CRISPR/Cas therapy, emphasizing the promise of recent preclinical and clinical trials while noting challenges in specificity, delivery, and clinical translatability.
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Phase 1 trial of NTLA-2001 (in vivo CRISPR) for transthyretin amyloidosis: single dose reduced serum TTR protein by up to 87% at day 28 with only mild adverse events in 6 patients.